Lincoln Pharmaceuticals Ltd. (BSE: 531633, NSE: LINCOLN), one of India’s leading healthcare companies has reported a consolidated net profit of Rs. 28.60 crore for the Q3 FY 2025-26 as compared to the net profit of Rs. 20.77 crore reported in Q3 FY 2024-25, increase of 37.70 % Y-o-Y. Revenue from Operation for the quarter ended December 2025 was reported at Rs. 166.32 crore as compared to the Rs. 146.55 crore in Q3 FY2024-25. EBITDA for Q3 FY26 was reported at Rs. 38.74 crore as compared to EBITDA of Rs. 32.63 crore in Q3 FY25 rise of 18.73 % Y-o-Y. EPS for Q3FY26 was reported at Rs. 14.28 per share.
CRISIL Ratings on 9th January has reaffirmed its ‘CRISIL A/Stable/CRISIL A1’ ratings on Lincoln Pharmaceuticals’ bank facilities, reflecting the promoters’ strong industry experience, established market position, and healthy financial profile, despite working-capital intensity and regulatory and competitive challenges. Company is targeting a revenue of Rs. 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. This goal is part of a broader strategy to achieve a 15-18% annual growth rate, driven by strong performance in the cardiac, diabetic, dermatology, and ENT segments. Company is committed to expanding its global footprint while meeting diverse healthcare needs. Foreign Institutional Investors (FIIs) holding in the company as on 31st December 2025 was 4.70%.
